UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 7, 2010
MEDIVATION, INC.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 001-32836 | | 13-3863260 |
(State or other jurisdiction of incorporation) | | (Commission File No.) | | (IRS Employer Identification No.) |
201 Spear Street, 3rd Floor
San Francisco, California 94105
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (415) 543-3470
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On December 7, 2010, Medivation, Inc. issued a press release entitled “Medivation Completes Enrollment in Phase 3 ‘CONCERT’ Trial of Dimebon Added to Donepezil in Patients with Alzheimer’s Disease.” A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
| | |
| 99.1 | | Press release, dated December 7, 2010, entitled “Medivation Completes Enrollment in Phase 3 ‘CONCERT’ Trial of Dimebon Added to Donepezil in Patients with Alzheimer’s Disease.” |
-1-
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| | | | MEDIVATION, INC. |
| | | |
| Dated: December 7, 2010 | | | | By: | | /s/ C. PATRICK MACHADO |
| | | | | | C. Patrick Machado Chief Business Officer and Chief Financial Officer |
EXHIBIT INDEX
| | |
| 99.1 | | Press release, dated December 7, 2010, entitled “Medivation Completes Enrollment in Phase 3 ‘CONCERT’ Trial of Dimebon Added to Donepezil in Patients with Alzheimer’s Disease.” |
